VWA5A antibody

Catalog No. ABIN7240895

Product Details anti-VWA5A Antibody

Target: VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This VWA5A antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Characteristics: Polyclonal Antibody

Purification: Affinity purification

Immunogen: Recombinant protein of human VWA5A

Isotype: IgG

Application Details

Application Notes: WB 1:500-1:2000, IHC 1:100-1:300

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Avoid freeze / thaw cycles.

Target Details for VWA5A

Target: VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))

Alternative Name: VWA5A (VWA5A Products)

Synonyms: VWA5A antibody, LOH11CR2A antibody, MGC68953 antibody, loh11cr2a antibody, BCSC-1 antibody, BCSC1 antibody, 5830475I06Rik antibody, AW552491 antibody, E130119J22 antibody, Loh11cr2a antibody, masa-1 antibody, loss of heterozygosity, 11, chromosomal region 2, gene A antibody, von Willebrand factor A domain containing 5A antibody, von Willebrand factor A domain containing 5A S homeolog antibody, LOH11CR2A antibody, VWA5A antibody, vwa5a.S antibody, vwa5a antibody, Vwa5a antibody

Background: VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80 % of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.

Molecular Weight: 86 kDa

UniProt: O00534